Survival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy

(MedPage Today) — CHICAGO — Patients with extensive-stage small-cell lung cancer (SCLC) lived significantly longer with the addition of cytotoxic agent lurbinectedin (Zepzelca) to maintenance immunotherapy, a large randomized trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115728

Author :

Publish date : 2025-05-22 21:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Survival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy

Mismatch Between Alzheimer’s Biomarkers and Symptoms May Signal Multiple Pathologies

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis

Related Posts

Minority Children Receive More Antibiotics for Pneumonia

Can Treating Siblings Aid Azithromycin’s Effect on Infants?

Why Your Arm Shape Skews Blood Pressure Readings

Can Preventing, Treating Herpes Reduce Dementia Risk?

Insufficient Sleep and Late Bedtimes: Early Puberty Risk?

Cannabis Use Disorder Tied to Benign Salivary Tumors

Minority Children Receive More Antibiotics for Pneumonia

Can Treating Siblings Aid Azithromycin’s Effect on Infants?

Why Your Arm Shape Skews Blood Pressure Readings

Can Preventing, Treating Herpes Reduce Dementia Risk?

Insufficient Sleep and Late Bedtimes: Early Puberty Risk?

Cannabis Use Disorder Tied to Benign Salivary Tumors

FDA Approves of VIZZ Eye Drops to Treat Presbyopia

Add-On Lobeglitazone Boosts Glycemic Control in T2D

Categories

Archives